Title: Production of 177Lu and formulation of Ethylene diamine tetramethylene phosphonate (EDTMP) kits as a bone-seeking radiopharmaceutical
Abstract: *Corresponding author: Mohammad Hossein Babaei, Radioisotope department, Nuclear Science Research School, Nuclear Science and Technology Research Institute, Atomic Energy Organization of Iran, Tehran, Iran Fax: +98 21 88221097 Email: [email protected] Background: Owing to its favourable decay characteristics 177Lu [T1/2= 6.71 d, Eβ(max)= 497 keV] is an attractive radionuclide for various therapeutic applications. Ethylene diamine tatramethylene phosphonate (EDTMP) is one of the most widely used ligands which form stable complexes with various radionuclides and all the complexes. Materials and Methods: Enriched 176Lu2O3 was dissolved in 0.1 N HCl and evaporated several times and 176LuCl3 target was irradiated at 2.6×1013 n.Cm2.S-1 thermal neutron flux for 14 days.177LuCl3 was dissolved in 1N HCl. EDTMP was dissolved in double distilled water at pH=7.5-8.5 and freeze-dried kits was radiolabeled with 177LuCl3. Distribution studies were done in healthy mice. Results: The yield of 177Lu was (~220 TBq/g; 6000 Ci/g), the radionuclidic purity was ~99%.The radiolabeling yield of EDTMP kits at 37°C after 30 min and 4 hours was 98±0.5% and after 72 hours was 90±2.1%, the in vitro stability in human serum at 37°C up to 72 hours post radiolabeling was 85±1.8%.The biodistribution studies of 177Lu-EDTMP and 177LuCl3 in normal mice showed skeleton uptake and low soft-tissue concentration. Conclusion: In this study, we produce ~220 TBq/g (6000 Ci/g) of 177Lu by neutron activation of 176Lu in the Tehran Research Reactor. Our results showed 177Lu-EDTMP as a bone-seeking radiopharmaceutical. Due to its suitable nuclear characteristics 177Lu appears to be worthwhile for palliative therapy of bone metastasis. Iran. J. Radiat. Res., 2010; 7 (4): 229 234
Publication Year: 2010
Publication Date: 2010-03-15
Language: en
Type: article
Access and Citation
Cited By Count: 9
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot